DelveInsight’s, “Type 1 Diabetes – Pipeline Insight, 2024” report provides comprehensive insights about 85+ companies and 100+ pipeline drugs in Type 1 Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As per DelveInsight, the Type 1 Diabetes therapeutics market is anticipated to evolve immensely in the coming years owing to the increasing prevalent population of Diabetes, increased healthcare spending worldwide, and the expected launch of emerging drugs in the market. Currently, key players such as Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, and several others are actively working in the Type 1 Diabetes therapeutics market.
Type 1 Diabetes Overview
Type 1 diabetes is an autoimmune disease where the body’s immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas, leading to a complete lack of insulin production. Insulin is essential for regulating blood sugar levels. The exact cause of this autoimmune destruction is unknown, but it is believed to involve a combination of genetic and environmental factors.
Causes and Risk Factors
– Genetic Factors: Having a first-degree relative (parent or sibling) with type 1 diabetes increases the risk. Certain genes are also linked to increased susceptibility.
– Environmental Triggers: Factors such as viral infections, exposure to certain chemicals, or dietary components like cow’s milk may contribute to the autoimmune response that destroys beta cells. However, the specific trigger remains unclear.
– Idiopathic Type 1 Diabetes: In 10-30% of cases where no autoimmunity is detected, the cause is unknown.
Symptoms
– Common Symptoms: Increased thirst, frequent urination (especially at night), extreme hunger, unintended weight loss, fatigue, weakness, blurred vision, irritability, and other mood changes.
– Additional Signs: Genital itching or thrush, slow-healing cuts and wounds, fruity-smelling breath.
– Symptoms in Children: Heavier diapers, bed-wetting in previously potty-trained children, fast breathing, belly pain, vomiting, behavior changes. Symptoms often appear suddenly and can progress rapidly over days or weeks.
Complications
Untreated type 1 diabetes can lead to life-threatening diabetic ketoacidosis, a condition characterized by high blood sugar and the buildup of ketones in the blood.
Treatment
– Insulin Therapy: The primary treatment involves administering insulin via injections or an insulin pump to regulate blood sugar levels.
– Carbohydrate Counting: Matching insulin doses with the amount of carbohydrates consumed is crucial.
– Glucose Monitoring: Continuous glucose monitoring (CGM) or flash glucose monitoring helps track blood sugar levels without frequent finger-prick tests.
– Additional Medications: Sometimes, medications like metformin are prescribed alongside insulin.
– Lifestyle Management: Maintaining a healthy diet, regular physical activity, and achieving a healthy weight are important for managing type 1 diabetes.
– Regular Check-ups: Ongoing care with a diabetes team, including an endocrinologist, certified diabetes educator, and registered dietitian, is necessary to monitor and adjust treatment as needed.
Prompt diagnosis and effective management are essential to control blood sugar levels and prevent complications associated with type 1 diabetes.
Type 1 Diabetes Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Type 1 Diabetes and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Type 1 Diabetes market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Type 1 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Intravenous
Subcutaneous
Molecule Type
The emerging pipeline products have been categorized under various Molecule types in the report, such as
Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy
Mechanism of Action of the Emerging Pipeline Therapies
CD40 antigen inhibitor
Interleukin 8A and 8B receptor antagonist
Ornithine decarboxylase stimulant
Glucagon receptor agonist
Cytotoxic T lymphocyte stimulant
Interleukin-2 replacement
Undefined mechanism
Learn How the Ongoing Clinical & Commercial Activities will Affect the Type 1 Diabetes Therapeutic Segment @ https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight
Type 1 Diabetes Therapeutics Landscape
There are approx. 85+ key companies developing therapies for Type 1 Diabetes. Currently, Eli Lilly and Company is leading the therapeutics market with its Type 1 Diabetes drug candidates in the most advanced stage of clinical development.
Leading Companies in the Type 1 Diabetes Therapeutics Market Include: Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, and many others.
Type 1 Diabetes Emerging and Marketed Drugs Profile:
AG019: Precigen ActoBiotics
AMTX 100: Amytrx
Basal insulin-Fc: Eli Lilly
Emricasan: Histogen
IMCY-0098: ImCyse
Insulin icodec: Novo Nordisk
Iscalimab: Novartis
Ladarixin: Dompe Pharmaceutical
LY3209590: Eli Lilly and Company Therapeutics
MHS552: Novartis
NNC0471-0119: Novo Nordisk
ORMD-0801: Oramed
Teplizumab: Prevention Bio
Volagidemab: REMD Biotherapeutics
VX-880: Vertex Pharmaceuticals
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight
Table of Contents
1. Report Introduction
2. Executive Summary
3. Type 1 Diabetes Current Treatment Patterns
4. Type 1 Diabetes – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Type 1 Diabetes Late Stage Products (Phase-III)
7. Type 1 Diabetes Mid-Stage Products (Phase-II)
8. Type 1 Diabetes Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Type 1 Diabetes Discontinued Products
13. Type 1 Diabetes Product Profiles
14. Key Companies in the Type 1 Diabetes Market
15. Key Products in the Type 1 Diabetes Therapeutics Segment
16. Dormant and Discontinued Products
17. Type 1 Diabetes Unmet Needs
18. Type 1 Diabetes Future Perspectives
19. Type 1 Diabetes Analyst Review
20. Appendix
21. Report Methodology
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
